ADPT logo

Adaptive Biotechnologies Corporation

ADPT
Healthcare|Biotechnology|US
$27.98
+1.15 (+4.29%)
Tangible Book / Share
$0.40
Cash / Share
$1.86
Next Earnings Report
Feb 4, 2027
EPS est. -$0.06 · Revenue est. $79.3M
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (3)

May 2027
Est. completion
P2Chronic Lymphocytic Leukemia (CLL)
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
NCT04419519n=81
Jul 2028
Est. completion
P2Mantle Cell Lymphoma
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
NCT06252675n=30
Apr 2029
Est. completion
P2Diffuse Large B-Cell Lymphoma (DLBCL)
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
NCT06828991n=40

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Dec 2025
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
NCT05271630

Recent Press Releases

Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
Nov 4, 2026 · GlobeNewsWire
Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026
Oct 14, 2026 · GlobeNewsWire
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
Sep 25, 2026 · GlobeNewsWire
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
Sep 17, 2026 · GlobeNewsWire
Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Sep 1, 2026 · GlobeNewsWire

SEC Filings (45)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 4, 202610-QQuarterly reportDocumentIndex
Nov 4, 20268-KMaterial eventDocumentIndex
Aug 4, 202610-QQuarterly reportDocumentIndex
Jul 29, 20268-KMaterial eventDocumentIndex
Jun 22, 20268-KMaterial eventDocumentIndex
Jun 15, 20268-KMaterial eventDocumentIndex
Jun 9, 20268-KMaterial eventDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 5, 202610-QQuarterly reportDocumentIndex
May 5, 20268-KMaterial eventDocumentIndex
Apr 24, 2026ARSAnnual report to holdersDocumentIndex
Apr 24, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 24, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 26, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 27, 2026S-8Employee stock planDocumentIndex
Feb 26, 202610-KAnnual reportDocumentIndex
Feb 5, 20268-KMaterial eventDocumentIndex
Jan 21, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 12, 20268-KMaterial eventDocumentIndex
Dec 30, 20258-KMaterial eventDocumentIndex
Nov 5, 202510-QQuarterly reportDocumentIndex
Nov 5, 20258-KMaterial eventDocumentIndex
Aug 18, 20258-KMaterial eventDocumentIndex
Aug 5, 202510-QQuarterly reportDocumentIndex
Aug 5, 20258-KMaterial eventDocumentIndex
Jul 9, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Jun 12, 20258-KMaterial eventDocumentIndex
Jun 6, 2025SC 13G/APassive 5%+ stakeDocumentIndex
May 14, 2025SC 13GPassive 5%+ stakeDocumentIndex
May 7, 2025SC 13G/APassive 5%+ stakeDocumentIndex
May 1, 202510-QQuarterly reportDocumentIndex
May 1, 20258-KMaterial eventDocumentIndex
Apr 29, 2025ARSAnnual report to holdersDocumentIndex
Apr 29, 2025DEFA14AProxy / shareholder voteDocumentIndex
Apr 29, 2025DEF 14AProxy / shareholder voteDocumentIndex
Apr 17, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Mar 3, 202510-KAnnual reportDocumentIndex
Feb 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Feb 13, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Feb 11, 20258-KMaterial eventDocumentIndex